¼¼°èÀÇ Ã·´Ü Ä¡·áÁ¦ ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)
Global Advanced Therapy Medicinal Products Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
÷´Ü Ä¡·áÁ¦ ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023-2030³âÀÇ Á¶»ç ±â°£ µ¿¾È CAGR 17.29%·Î ¼ºÀåÇÏ¿© 2022³â 285¾ï 6,000¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 1,022¾ï 9,000¸¸ ´Þ·¯¿¡ À°¹ÚÇÏ´Â ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
÷´Ü Ä¡·áÁ¦(ATMP)´Â ¼¼Æ÷ ¶Ç´Â À¯ÀüÀÚ ¼öÁØ¿¡¼ Áúº´°ú ºÎ»óÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ´Ù¾çÇÑ Ã·´Ü ÀÇ·áÁ¦Ç°À» Æ÷°ýÇÏ´Â Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ ¹üÁÖÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº À¯ÀüÀÚ, ¼¼Æ÷ ¹× Á¶Á÷À» Ȱ¿ëÇÏ¿© ƯÁ¤ Áúº´ ¹× º´¸®¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ÀÇ·á¿¡ »õ·Î¿î Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
½ÃÀå ¿ªÇÐ
÷´Ü Ä¡·áÁ¦(ATMPs) ½ÃÀåÀº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ù°, ATMPs´Â Áö±Ý±îÁö Ä¡·áÇÒ ¼ö ¾ø°Å³ª Àß °ü¸®µÇÁö ¾Ê´Â Áúº´À» Ä¡·áÇϰí, ¾Ï, À¯Àü¼º Áúȯ, ÅðÇ༺ Áúȯ°ú °°Àº ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¸¦ ÇØ°áÇØÁÝ´Ï´Ù. »ý¸í°øÇÐ, À¯ÀüÀÚ ÆíÁý, Á¶Á÷°øÇÐ ºÐ¾ßÀÇ ±â¼ú ¹ßÀüÀº ATMPÀÇ °³¹ß ¹× »ó¿ëÈ¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. °³¼±µÈ ±â¼úÀº ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» Çâ»ó½ÃÄÑ Ä¡·á¹ýÀÇ Ã¤Åðú ½ÃÀå È®´ë¸¦ ÃËÁøÇÕ´Ï´Ù. Áö¿øÀûÀÎ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ½Å¼ÓÇÑ ½ÂÀÎ °æ·Î´Â ATMP¿¡ ´ëÇÑ ¿¬±¸¿Í ÅõÀÚ¸¦ ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ, R&D¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í Á¦¾àȸ»ç, »ý¸í°øÇÐ ±â¾÷ ¹× ÇаèÀÇ Çù·ÂÀº ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¸ÂÃãÀÇ·á·ÎÀÇ ÀüȯÀº ATMP°¡ Á¦°øÇϴ ǥÀûÄ¡·áÁ¦¿Í ¸ÂÃãÄ¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
Á¶»ç º¸°í¼´Â Portre's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â °í±Þ Ä¡·áÁ¦ ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÷´Ü Ä¡·áÁ¦ »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
Áö¿ª ºÐ¼®
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ã·´Ü Ä¡·áÁ¦ ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ÀÌ º¸°í¼´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.
¿äûÀÌ ÀÖÀ¸½Ã¸é ´ç»ç·Î ¿¬¶ôÁֽʽÿÀ. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå ÁÖ¿ä ¿ä¾à
- ½ÃÀå ÇÏÀ̶óÀÌÆ®
- ¼¼°è ½ÃÀå ÇöȲ
Á¦3Àå ÷´Ü Ä¡·áÁ¦ - »ê¾÷ ºÐ¼®
- ¼·Ð : ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
- ¾÷°è µ¿Çâ
- PorterÀÇ Five Forces ºÐ¼®
- ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®
- ¹ë·ùüÀÎ ºÐ¼®
- ¿øÀç·á ºÐ¼®
- ¿øÀç·á ¸®½ºÆ®
- ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
- ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
- ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
- ¸¶ÄÉÆÃ Ã¤³Î
- Á÷Á¢ ¸¶ÄÉÆÃ
- °£Á¢ ¸¶ÄÉÆÃ
- ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ
Á¦5Àå ¼¼°èÀÇ Ã·´Ü Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°
- Ä¡·á À¯Çüº° °³¿ä
- ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
- Ä¡·á À¯Çüº° ºÐ¼®
- ¼¼Æ÷Ä¡·á(Áٱ⼼Æ÷ ¿ä¹ý, ºñÁٱ⼼Æ÷ ¿ä¹ý)
- À¯ÀüÀÚ Ä¡·á
- Á¶Á÷°øÇÐ Á¦Ç°
Á¦6Àå ¼¼°èÀÇ Ã·´Ü Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Áö¿ªº°
- Áö¿ªº° Àü¸Á
- ¼·Ð
- ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- ºÏ¹Ì : ºÎ¹®º°
- ºÏ¹Ì : ±¹°¡º°
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- À¯·´ : ºÎ¹®º°
- À¯·´ : ±¹°¡º°
- ¿µ±¹
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- È£ÁÖ
- µ¿³²¾Æ½Ã¾Æ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
- ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Æä·ç
- Ä¥·¹
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
- °³¿ä, ½ÇÀû°ú ¿¹Ãø
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ÆÇ¸Å ºÐ¼®
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- À̽º¶ó¿¤
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦7Àå ÷´Ü Ä¡·áÁ¦ ±â¾÷ÀÇ °æÀï ±¸µµ
- ÷´Ü Ä¡·áÁ¦ ½ÃÀå °æÀï
- Á¦ÈÞ/Çù·Â/ÇÕÀÇ
- ÀμöÇÕº´(M&A)
- ½ÅÁ¦Ç° Ãâ½Ã
- ±âŸ °³¹ß
Á¦8Àå ±â¾÷ °³¿ä
- ±â¾÷ Á¡À¯À² ºÐ¼®
- ½ÃÀå ÁýÁßµµ
- Spark Therapeutics Inc.
- Bluebird Bio Inc.
- Novartis AG
- UniQure N.V.
- Celgene Corporation
- Gilead Lifesciences Inc.
- Kolon TissueGene Inc.
- JCR Pharmaceuticals Co. Ltd.
- Medipost
- Vericel Corporation
- Pharmicell Co. Ltd
- Organogenesis Inc.
LSH
The global demand for Advanced Therapy Medicinal Products Market is presumed to reach the market size of nearly USD 102.29 BN by 2030 from USD 28.56 BN in 2022 with a CAGR of 17.29% under the study period 2023 - 2030.
Advanced therapy medicinal products (ATMPs) are a category of innovative therapies that encompass a range of cutting-edge medical products used to treat diseases and injuries at the cellular or genetic level. These therapies offer novel approaches to medical treatment by utilizing genes, cells, or tissues to target specific diseases or conditions.
MARKET DYNAMICS
The Advanced therapy medicinal products (ATMPs) market is experiencing growth driven by several key factors. Firstly, these therapies address previously untreatable or inadequately managed diseases, catering to unmet medical needs in conditions like cancer, genetic disorders, and degenerative diseases. Technological advancements in biotechnology, gene editing, and tissue engineering significantly contribute to the development and commercialization of ATMPs. Improved technologies enhance the efficacy and safety of these therapies, fostering their adoption and market expansion. Supportive regulatory frameworks and expedited approval pathways encourage research and investment in ATMPs. Additionally, increased investments in research and development, coupled with collaborations between pharmaceutical companies, biotech firms, and academic institutions, drive innovation in this field. The rising prevalence of chronic diseases worldwide, coupled with the shift towards personalized medicine, further amplifies the demand for targeted and personalized therapies offered by ATMPs.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of advanced therapy medicinal products. The growth and trends of advanced therapy medicinal products industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the advanced therapy medicinal products market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Therapy Type
- Cell Therapy (Stem Cell Therapy, Non-Stem Cell Therapy)
- Gene Therapy
- Tissue Engineered Product
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Advanced Therapy Medicinal Products market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Advanced Therapy Medicinal Products market include Spark Therapeutics Inc., Bluebird Bio Inc., Novartis AG, UniQure N.V., Celgene Corporation, Gilead Lifesciences Inc., Kolon TissueGene Inc., JCR Pharmaceuticals Co. Ltd., Medipost, Vericel Corporation, Pharmicell Co. Ltd, Organogenesis Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . ADVANCED THERAPY MEDICINAL PRODUCTS - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET ANALYSIS BY THERAPY TYPE
- 5.1 Overview by Therapy Type
- 5.2 Historical and Forecast Data
- 5.3 Analysis by Therapy Type
- 5.4 Cell Therapy (Stem Cell Therapy, Non-stem Cell Therapy) Historic and Forecast Sales by Regions
- 5.5 Gene Therapy Historic and Forecast Sales by Regions
- 5.6 Tissue Engineered Product Historic and Forecast Sales by Regions
6 . GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET ANALYSIS BY GEOGRAPHY
- 6.1. Regional Outlook
- 6.2. Introduction
- 6.3. North America Sales Analysis
- 6.3.1. Overview, Historic and Forecast Data Sales Analysis
- 6.3.2. North America By Segment Sales Analysis
- 6.3.3. North America By Country Sales Analysis
- 6.3.4. United State Sales Analysis
- 6.3.5. Canada Sales Analysis
- 6.3.6. Mexico Sales Analysis
- 6.4. Europe Sales Analysis
- 6.4.1. Overview, Historic and Forecast Data Sales Analysis
- 6.4.2. Europe by Segment Sales Analysis
- 6.4.3. Europe by Country Sales Analysis
- 6.4.4. United Kingdom Sales Analysis
- 6.4.5. France Sales Analysis
- 6.4.6. Germany Sales Analysis
- 6.4.7. Italy Sales Analysis
- 6.4.8. Russia Sales Analysis
- 6.4.9. Rest Of Europe Sales Analysis
- 6.5. Asia Pacific Sales Analysis
- 6.5.1. Overview, Historic and Forecast Data Sales Analysis
- 6.5.2. Asia Pacific by Segment Sales Analysis
- 6.5.3. Asia Pacific by Country Sales Analysis
- 6.5.4. China Sales Analysis
- 6.5.5. India Sales Analysis
- 6.5.6. Japan Sales Analysis
- 6.5.7. South Korea Sales Analysis
- 6.5.8. Australia Sales Analysis
- 6.5.9. South East Asia Sales Analysis
- 6.5.10. Rest Of Asia Pacific Sales Analysis
- 6.6. Latin America Sales Analysis
- 6.6.1. Overview, Historic and Forecast Data Sales Analysis
- 6.6.2. Latin America by Segment Sales Analysis
- 6.6.3. Latin America by Country Sales Analysis
- 6.6.4. Brazil Sales Analysis
- 6.6.5. Argentina Sales Analysis
- 6.6.6. Peru Sales Analysis
- 6.6.7. Chile Sales Analysis
- 6.6.8. Rest of Latin America Sales Analysis
- 6.7. Middle East & Africa Sales Analysis
- 6.7.1. Overview, Historic and Forecast Data Sales Analysis
- 6.7.2. Middle East & Africa by Segment Sales Analysis
- 6.7.3. Middle East & Africa by Country Sales Analysis
- 6.7.4. Saudi Arabia Sales Analysis
- 6.7.5. UAE Sales Analysis
- 6.7.6. Israel Sales Analysis
- 6.7.7. South Africa Sales Analysis
- 6.7.8. Rest Of Middle East And Africa Sales Analysis
7 . COMPETITIVE LANDSCAPE OF THE ADVANCED THERAPY MEDICINAL PRODUCTS COMPANIES
- 7.1. Advanced Therapy Medicinal Products Market Competition
- 7.2. Partnership/Collaboration/Agreement
- 7.3. Merger And Acquisitions
- 7.4. New Product Launch
- 7.5. Other Developments
8 . COMPANY PROFILES OF ADVANCED THERAPY MEDICINAL PRODUCTS INDUSTRY
- 8.1. Company Share Analysis
- 8.2. Market Concentration Rate
- 8.3. Spark Therapeutics Inc.
- 8.3.1. Company Overview
- 8.3.2. Company Revenue
- 8.3.3. Products
- 8.3.4. Recent Developments
- 8.4. Bluebird Bio Inc.
- 8.4.1. Company Overview
- 8.4.2. Company Revenue
- 8.4.3. Products
- 8.4.4. Recent Developments
- 8.5. Novartis AG
- 8.5.1. Company Overview
- 8.5.2. Company Revenue
- 8.5.3. Products
- 8.5.4. Recent Developments
- 8.6. UniQure N.V.
- 8.6.1. Company Overview
- 8.6.2. Company Revenue
- 8.6.3. Products
- 8.6.4. Recent Developments
- 8.7. Celgene Corporation
- 8.7.1. Company Overview
- 8.7.2. Company Revenue
- 8.7.3. Products
- 8.7.4. Recent Developments
- 8.8. Gilead Lifesciences Inc.
- 8.8.1. Company Overview
- 8.8.2. Company Revenue
- 8.8.3. Products
- 8.8.4. Recent Developments
- 8.9. Kolon TissueGene Inc.
- 8.9.1. Company Overview
- 8.9.2. Company Revenue
- 8.9.3. Products
- 8.9.4. Recent Developments
- 8.10. JCR Pharmaceuticals Co. Ltd.
- 8.10.1. Company Overview
- 8.10.2. Company Revenue
- 8.10.3. Products
- 8.10.4. Recent Developments
- 8.11. Medipost
- 8.11.1. Company Overview
- 8.11.2. Company Revenue
- 8.11.3. Products
- 8.11.4. Recent Developments
- 8.12. Vericel Corporation
- 8.12.1. Company Overview
- 8.12.2. Company Revenue
- 8.12.3. Products
- 8.12.4. Recent Developments
- 8.13. Pharmicell Co. Ltd
- 8.13.1. Company Overview
- 8.13.2. Company Revenue
- 8.13.3. Products
- 8.13.4. Recent Developments
- 8.14. Organogenesis Inc.
- 8.14.1. Company Overview
- 8.14.2. Company Revenue
- 8.14.3. Products
- 8.14.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies